Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PHAT 
Phathom Pharmaceuticals Inc (PHAT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: PHAT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $21.38
1 Year Target Price $21.38
| 6 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 27.36% | Avg. Invested days 40 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 778.96M USD | Price to earnings Ratio - | 1Y Target Price 21.38 |
Price to earnings Ratio - | 1Y Target Price 21.38 | ||
Volume (30-day avg) 9 | Beta 0.44 | 52 Weeks Range 2.21 - 19.71 | Updated Date 09/17/2025 |
52 Weeks Range 2.21 - 19.71 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.67 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -289.51% | Operating Margin (TTM) -151.7% |
Management Effectiveness
Return on Assets (TTM) -59.03% | Return on Equity (TTM) -3489% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 870830767 | Price to Sales(TTM) 6.83 |
Enterprise Value 870830767 | Price to Sales(TTM) 6.83 | ||
Enterprise Value to Revenue 7.64 | Enterprise Value to EBITDA -2.2 | Shares Outstanding 70943696 | Shares Floating 51189419 |
Shares Outstanding 70943696 | Shares Floating 51189419 | ||
Percent Insiders 4.2 | Percent Institutions 83.96 |
Upturn AI SWOT
Phathom Pharmaceuticals Inc
Company Overview
History and Background
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. Founded in 2019, Phathom's initial focus was on vonoprazan, a potassium-competitive acid blocker (PCAB), and its potential to address unmet needs in acid-related GI disorders.
Core Business Areas
- Gastrointestinal Disease Treatments: Phathom focuses on the development and commercialization of therapies for gastrointestinal diseases, particularly those related to acid production and imbalance.
Leadership and Structure
The leadership team includes individuals with experience in pharmaceutical development, commercialization, and business management. The organizational structure is typical of a biopharmaceutical company, with departments focused on research and development, clinical trials, regulatory affairs, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Vonoprazan: Vonoprazan is a potassium-competitive acid blocker (PCAB) for the treatment of acid-related GI disorders. The product is commercialized as VOQUEZNA. Competitors include Proton Pump Inhibitors (PPIs) like omeprazole (Prilosec), esomeprazole (Nexium), and lansoprazole (Prevacid). Currently VOQUEZNA market share is low due to a recent recall.
Market Dynamics
Industry Overview
The pharmaceutical industry targeting gastrointestinal disorders is large and competitive, with a significant market for acid-reducing medications. Growth is driven by increasing prevalence of GI conditions such as GERD, peptic ulcers, and H. pylori infections.
Positioning
Phathom is positioned as an innovator in the GI space with its PCAB technology. The company seeks to differentiate itself from traditional PPIs through potentially faster onset of action and more consistent acid suppression.
Total Addressable Market (TAM)
The global market for gastrointestinal drugs is estimated to be over $50 billion. Phathom aims to capture a portion of this TAM by offering improved treatment options for acid-related disorders. TAM expectations were adjusted down after recent VOQUEZNA recall.
Upturn SWOT Analysis
Strengths
- Novel PCAB technology
- Potential for improved efficacy compared to PPIs
- Experienced management team
Weaknesses
- Dependence on a single product (vonoprazan)
- Recent product recall and associated cost
- Limited commercial infrastructure compared to larger pharmaceutical companies
- Need for additional funding to support ongoing research and commercialization
Opportunities
- Expansion into new indications for vonoprazan
- Partnerships with larger pharmaceutical companies
- Geographic expansion into new markets
- Development of follow-on products
- Favorable clinical trial results and regulatory approvals
Threats
- Competition from established PPIs and other acid-reducing medications
- Regulatory hurdles and delays
- Patent challenges
- Adverse events or safety concerns
- Reimbursement challenges from payers
Competitors and Market Share
Key Competitors
- AZN
- TAK
Competitive Landscape
Phathom faces significant competition from established pharmaceutical companies with well-established PPI products. The company's advantage lies in the potential for improved efficacy of vonoprazan, but it must overcome the challenge of competing with larger companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's focus on clinical development and regulatory approvals. Some growth followed the initial launch of VOQUEZNA, however revenue has decreased in the wake of the recall.
Future Projections: Future growth depends on the successful commercialization of vonoprazan and the development of new products. Analyst estimates vary, but generally project significant revenue growth if the product re-enters the market successfully.
Recent Initiatives: Recent initiatives include efforts to address the issue related to the VOQUEZNA recall and secure funding for ongoing operations.
Summary
Phathom Pharmaceuticals is a high-risk, high-reward biopharmaceutical company. The company needs to resolve the VOQUEZNA recall quickly and effectively. Phathom has an opportunity to become a significant player in the GI market with successful resolution and relauch. The financial situation of Phathom Pharmaceutical remains weak.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Analyst reports, Press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investing in pharmaceutical companies is inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Phathom Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2019-10-25 | CEO, President & Director Mr. Steven L. Basta M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 427 | Website https://www.phathompharma.com |
Full time employees 427 | Website https://www.phathompharma.com | ||
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.